Evidence map›Paper›PMID 37013558›Full record

ArticleTrials2023

Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries.

Kelsey McDonald, Earl Seltzer, Mary Lu, Stefan Diaz Gaisenband, Cassandra Fletcher, Patrick McLeroth, Kamal S Saini

Abstract readLetter
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Videoconferencing with the Hospitalized Premature Infant while Expressing Milk: A Randomized Crossover Trial.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2026
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Educators, Not Influencers: Health Content Creator Perspectives on Research Recruitment Collaboration.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kelsey McDonaldLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Earl SeltzerLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Mary LuLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Stefan Diaz GaisenbandLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Cassandra FletcherLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Patrick McLerothLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA.
Kamal S SainiLabcorp Drug Development Inc, 206 Carnegie Center Dr, Princeton, NJ, 08540, USA. Kamal.saini@nhs.net.ORCID http://orcid.org/0000-0001-6301-3309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has had an unprecedented and disruptive impact on people's health and lives worldwide. In addition to burdening people's health in the short-term in the form of infection, illness, and mortality, there has been an enormous negative impact on clinical research. Clinical trials experienced challenges in ensuring patient safety and enrolling new patients throughout the pandemic. Here, we investigate and quantify the negative impact that the COVID-19 pandemic has industry-sponsored clinical trials, both in the USA and worldwide. We find a negative correlation between the severity of the COVID-19 pandemic and clinical trial screening rate, with the relationship being strongest during the first three months of the pandemic compared to the entire duration of the pandemic. This negative statistical relationship holds across therapeutic areas, across states in the USA despite the heterogeneity of responses at the state-level, and across countries. This work has significant implications for the management of clinical trials worldwide in response to the fluctuating severity of COVID-19 moving forward and for future pandemics.

Indexed as

COVID-19HumansPandemicsPatient SafetySARS-CoV-2Clinical trialsCoronavirusCOVID-19EnrollmentGlobalImpactPandemicRecruitmentSARS-CoV-2Screening

Identifiers

PMID37013558
PMCPMC10071259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.